Whitepaper
One Partner, Every Phase
Navigating the market journey of your therapeutic oligonucleotides
Explore CDMO selection, technology transfer, analytical continuity and GMP readiness, with case studies from development through commercial supply.
About this whitepaper
Whether you are advancing an oligonucleotide therapy into the clinic, preparing for GMP manufacturing, planning a technology transfer or building commercial supply, each phase brings critical decisions. Multiple vendors, changing processes, evolving regulatory expectations and inconsistent analytical methods can add complexity. This whitepaper examines how a CDMO partnership can help coordinate work across these stages.
What you’ll learn
- Key development risks from early-stage material supply to clinical and commercial GMP manufacturing.
- How a single CDMO partnership can help reduce technology-transfer burden and maintain analytical continuity.
- CDMO selection criteria, including scalability, regulatory support, impurity control and supply chain resilience.
- BioSpring case studies on GMP onboarding, late-stage technology transfer, process validation and commercial readiness.
Who is it for?
Program leaders and CMC, process development and sourcing teams evaluating oligonucleotide CDMO partnerships.